19 results about "Antiangiogenic therapy" patented technology

Provided are methods, compositions, and kits for treating metastatic cancer in a subject. In some embodiments, methods may include administering a treatment including inhibition of angiogenesis and a PLK1 inhibitor (e.g., onvansertib) to a subject that has not yet undergone past anti-angiogenesis treatment in a manner sufficient to reduce or inhibit metastatic cancer progression.

The invention discloses an application of a tumor targeting NNMT inhibitor in preparation of a drug-resistant tumor resistant drug. The NNMT inhibitor comprises an NNMT inhibitor dipeptide and a physiologically acceptable salt of the NNMT inhibitor dipeptide. The NNMT inhibitor can target tumor microenvironment FAP < + > / NNMT < + > extravascular stromal cells, reduce the expression of drug resistance promoting factors, induce blood vessel normalization, improve the infiltration of killer T cells, block the formation of tumor immunosuppression microenvironment, and enhance the curative effects of tumor immunotherapy and anti-angiogenesis therapy. The NNMT inhibitor has a remarkable immunotherapy or anti-angiogenesis treatment sensitization effect on colorectal cancer, pancreatic cancer, breast cancer, lung cancer, liver cancer, stomach cancer, prostatic cancer, ovarian cancer, melanoma and the like, and has a good application prospect in the aspect of preparing anti-drug-resistant tumor drugs.

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

The present invention concerns anti-angiogenic therapies for the treatment of ovarian cancer. In general, the present invention concerns the treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using anti-VEGF antibodies, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.

The present invention refers to an amorphous form of cabozantinib sulphate monohydrate and a process for its preparation, a pharmaceutical composition comprising it, and its use for the the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC) and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy treatment of cancer.

The present invention belongs to the field of biomedicine, and specifically relates to the use of recombinant human endostatin adenovirus and anti-PD-1 antibody or anti-PD-L1 antibody in the preparation of anti-tumor drugs. The technical problem to be solved by the present invention is to provide a drug with good anti-tumor effect. The technical solution to the technical problem of the present invention is to provide an anti-tumor drug containing an adenovirus encoding human endostatin and anti-PD-1 antibody or anti-PD-L1 antibody as main active ingredients. The co-treatment of adenovirus encoding human endostatin and anti-PD-1 antibody or anti-PD-L1 antibody can effectively inhibit tumor growth, cause tumor regression without recurrence, and no obvious toxic side effects are observed, indicating that the combination of anti-angiogenic therapy containing adenovirus encoding human endostatin and immunotherapy with anti-PD-1 antibody or anti-PD-L1 antibody is an effective method for treating tumors and has good application prospects.

The invention relates to a platelet-derived growth factor receptor beta (PDGFR beta) targeting inhibitor, a radioactive probe and application, and belongs to the field of nuclear medicine imaging agents and nuclide radiotherapy agents. The inhibitor is at least one of compounds shown in a formula I, and the radioactive probe is at least one of compounds shown in a formula II. The PDGFR beta targeting radioactive probe provided by the invention can specifically target a PDGFR beta high-expression tumor, and has good tumor uptake and rapid in-vivo metabolism properties. The targeted PDGFRbeta radioactive probe provided by the invention has a relatively good tumor ratio, can be rapidly metabolized and discharged out of a body through the kidney, and has an important clinical application value for early precise diagnosis and targeted radioactive treatment of PDGFRbeta positive tumors and screening of people benefitting an anti-angiogenesis treatment strategy.

The present invention refers to a novel crystalline polymorphic form of cabozantinib hemifumarate sesquihydrate designated as Form A, a novel crystalline polymorphic form of cabozantinib hemifumarate hemipentahydrate designated as Form B and a process for their preparation, a pharmaceutical composition comprising Form A or Form B, and their use for the the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC) and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy treatment of cancer.

The present invention refers to a crystalline form of cabozantinib hemi-(S)-malate designated as Form A and a process for its preparation, a pharmaceutical composition comprising it, and its use for the the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC) and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy treatment of cancer.

The invention discloses VEGF (Vascular Endothelial Growth Factor) combined oligopeptide and application thereof in preparation of an anti-angiogenesis therapeutic drug. Compared with the existing anti-VEGF monoclonal antibody and fusion protein, the oligopeptide inhibitor prepared by the recombinant protein expression system has the remarkable advantages of small molecule drugs while keeping the stability of traditional biological products. The invention creates a novel VEGF inhibitor which has binding capacity and is easy to accurately regulate and control through bioengineering, and provides an innovative solution with both transformation efficiency and clinical potential for next-generation anti-angiogenesis treatment.

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

The present invention relates to an inhibitor targeting platelet-derived growth factor receptor β (PDGFRβ), a radioactive probe and their applications, belonging to the fields of nuclear medicine imaging agents and radionuclide radiotherapy agents. The inhibitor of the present invention is at least one of the compounds shown by formula I, and the radioactive probe is at least one of the compounds shown by formula II. The radioactive probe targeting PDGFRβ provided by the present invention can specifically target tumors with high expression of PDGFRβ, and has good tumor uptake and rapid in vivo metabolism properties. The radioactive probe targeting PDGFRβ provided by the present invention has a good tumor-to-background ratio, can be rapidly metabolized and excreted from the body through the kidneys, and has important clinical application value for the early and accurate diagnosis and targeted radiotherapy of PDGFRβ-positive tumors and screening of beneficiaries of anti-angiogenic treatment strategies.

The invention discloses application of a combination of a ferroptosis inducer and an anti-angiogenesis medicine in preparation of a medicine for treating tumors, the ferroptosis inducer is selected from one or more of Erastatin, RSL3, FIN56 and FIN02, the anti-angiogenesis medicine is DC101, and the tumors comprise one or more of melanoma, lung cancer, pancreatic cancer, gastric cancer, kidney cancer, colon cancer, breast cancer and liver cancer. Particularly, the ferroptosis inducer Erastatin and the anti-angiogenesis medicine DC101 are combined for use, and the use dosages of the ferroptosis inducer Erastatin and the anti-angiogenesis medicine DC101 are respectively 1-40 mg / kg and 1-20 mg / kg. The invention further provides a pharmaceutical composition containing the Erasttin and the DC101. The invention further provides the pharmaceutical composition containing the Erasttin and the DC101. The tumor treatment effect is improved by adopting a treatment mode of combining the ferroptosis inducer and the anti-angiogenesis medicine, the problem that the anti-angiogenesis treatment effect is poor is solved, the prognosis of tumor patients is improved, and the application has a wide clinical application prospect.

Described herein are anti-angiogenic therapies and compounds for use in anti-angiogenic therapies, particularly for disorders associated with abnormal excess production of abnormal angiogenesis or pro-angiogenic VEGFxxx isoforms within or on the eye.

The present invention refers to a crystalline form of cabozantinib L-tartrate designated as Form A and a process for its preparation, a pharmaceutical composition comprising it, and its use for the the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC) and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy treatment of cancer.

Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.

The application discloses a kind of pharmaceutical composition, medicine and application for treating tumor, belong to combined medication technical field.The application provides a kind of pharmaceutical composition for treating tumor, antiangiogenic drug and HIF-1a inhibitor are combined with drug.The application proves that the hypoxic microenvironment of antiangiogenic therapy induced gastric cancer promotes the accumulation of intracellular HIF-1a, and HIF-1a reprograms the hypoxia tolerance of cell by enhancing glucose metabolism, so that gastric cancer cells maintain viability in hypoxic microenvironment.The application can produce synergistic complementary effect by the way of combined treatment of antiangiogenic drug apatinib and HIF-1a inhibitor CAY10585: aggravate intratumoral hypoxia of gastric cancer, block glucose metabolic reprogramming of gastric cancer cells, and then enhance anti-tumor effect, inhibit the progress of gastric cancer.

The application provides a kind of drug composition in the preparation for the application of the drug for the maintenance treatment of disease control ES-SCLC after first-line chemotherapy, belong to the biomedicine technical field.The drug composition is carimab and apatinib.The application finds that carimab is combined with apatinib as maintenance treatment, shows encouraging efficacy and acceptable safety in ES-SCLC patient who is not in progress after first-line chemotherapy, the median overall survival (OS) is 25.00 months, and the 12-month OS rate is 71.4%.This strategy of simultaneously targeting PD-1 and VEGFR2 provides a novel and reasonable solution for extending the disease control period in malignant tumors with limited treatment options after induction therapy, not only solves the key needs of ES-SCLC patients for more effective maintenance treatment, but also provides important insights into the biological principles of anti-angiogenic therapy combined with immunotherapy.

The present disclosure relates to an anti-PTK7 chimeric antibody, an anti-PTK7 humanized antibody, and uses thereof. According to the present invention, it was confirmed that the anti-PTK7 chimeric antibody and anti-PTK7 humanized antibody, which specifically bind to PTK7, suppress oncogenicity such as wound regeneration, migration, and invasion of cells derived from PTK7-expressing cancers, such as esophageal squamous cell carcinoma, triple-negative breast cancer, and the like, and inhibit tumor growth and in vivo angiogenesis in xenograft animal models of these cancers. Therefore, the antibodies can be used as anticancer therapeutic agents for various PTK7-positive cancers and therapeutic agents for angiogenic diseases. In addition, these antibodies can be used alone, in combination with drugs such as existing anticancer drugs with known efficacy, or in the form of antibody-drug conjugates for anticancer and anti-angiogenic therapy.